Cantor Fitzgerald analyst Louise Chen raised the firm’s price target on Merck to $135 from $120 and keeps an Overweight rating on the shares. Chen has greater confidence in Merck’s ability to extend its earnings growth following Keytruda’s loss of exclusivity in 2028, and continues to look forward to several upcoming potential catalysts, including its sNDA for Lynparza + abiraterone for the treatment of adult patients with metastatic castration-resistant prostate cancer, the analyst tells investors in a research note.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on MRK:
- Moderna price target raised to $209 from $170 at Morgan Stanley
- IMV Blasts Up after New Test Data Emerges
- Street Wrap: Today’s Top 15 Upgrades, Downgrades, Initiations
- Vaxcyte initiated with a Buy at Guggenheim on pneumococcal vaccine potential
- BioNTech upgraded to Buy at BofA oncology pipeline opportunities
